PT  - JOURNAL ARTICLE
AU  - Patricio Vargas
AU  - Sebastián Allende
AU  - Eugenio E. Vogel
AU  - Sigismund Kobe
TI  - Rapid characterization of the propagation of COVID-19 in different countries
AID  - 10.1101/2020.06.09.20126631
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.09.20126631
4099  - http://medrxiv.org/content/early/2020/06/11/2020.06.09.20126631.short
4100  - http://medrxiv.org/content/early/2020/06/11/2020.06.09.20126631.full
AB  - BACKGROUND COVID-19 has spread rapidly, and there are still many characteristics of this new disease to be unveiled. We propose a simple method to calculate a “figure of merit” FC to provide an early characterization of the disease status in country C.METHODS We use mathematical tools to adjust a Gaussian function to the daily increase of infected patients. Maximum value and full width half maximum of the Gaussian are characteristics of the development of the development of the pandemic in each country. These parameters are supplemented by the testing volume and the mortality rate to produce just one characterizing parameter: FC. In addition, the stability of the Gaussian fits was calculated within an entire week towards the end of the study period. Seventeen different countries were fully considered, while others are considered when discussing particular properties. Data employed is publically available.FINDINGS Fitted Gaussian functions render effective information about the development of COVID-19. The number of critical days vary between 11 (South Korea) and 52 (Mexico). FC varies between 1 (Australia) and 899 (Mexico). The epidemic appears stabilized in some countries and unstable in others. Some large countries are experiencing fast development of the propagation of the disease with high FC. A correlation between low (high) values of the mortality rate (and to some extent FC) and the presence (absence) of BCG vaccination is exposed.INTERPRETATION The adjustment of a Gaussian to daily data of COVID-19 in each country reveals the different propagation dynamics, properly characterized by the parameters proposed here. Testing plays a clear role to control the spread of the disease. Mortality rate spans more than one order of magnitude and is somewhat related to permanent massive BCG vaccination. The figure of merit, FC, introduced here spans more than 2 orders of magnitude which makes it a useful indicator to quickly find out the status of the pandemics in each territory. Geography plays a role: low population density and isolated countries can be efficient in controlling the spread of the disease.HIGHLIGHTSAn easy-to-evaluate parameter is defined to rapidly establish the status of the evolution of COVID-19 in any given territory. 17 countries in 4 continents are chosen to apply it and compare different evolutions.The parameter or figure of merit (FC) is dynamic: it combines testing, mortality rate, and characteristics of the Gaussian function that fits the new daily contagions.FC spans more than two orders of magnitude which makes it a very sensitive indicator to promptly detect second waves or local outbreaks.It is found that countries with massive BCG vaccination present low COVID-19 mortality rates and low values for FC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementConicyt (Chile) as quoted in the paperAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a statistical paper based on public data; no patients are considered.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAl data are public and properly quoted in the paper.